New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 13, 2013
13:23 EDTNEPTNeptune increases equity participation in Acasti Pharma
Neptune Technologies & Bioressources announces it has acquired, through the exercise of a previously issued warrant, 6,750,000 Class A common shares in the capital of Acasti Pharma, a majority-owned subsidiary of Neptune. The shares were acquired at a price of CDN$2.30 per Share upon the exercise of the warrant. This reflects a total exercise price of approximately CDN$15.5M. The warrant was delivered to Neptune pursuant to a royalty prepayment agreement, dated December 4, 2012, entered into between Neptune and Acasti, under which Acasti has exercised the option embedded in its exclusive technology license agreement dated August 7, 2008 entered into between Acasti and Neptune to pay in advance all of the future royalties payable under the License Agreement. As a result of the royalty prepayment transaction, Acasti is no longer required to pay any royalties to Neptune under the License Agreement during its term for the use of the intellectual property under license. The exercise of the warrant has increased Neptune's equity participation in Acasti from approximately 57% to approximately 60% as at July 12.
News For NEPT From The Last 14 Days
Check below for free stories on NEPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2014
12:59 EDTNEPTNeptune shares higher by over 3% after U.S grants patent related to Alzheimer's
Earlier today, Neptune Technologies & Bioressources announced that the U.S. Patent & Trademark Office, USPTO, has granted Neptune a new continuation patent relating to the treatment of Alzheimer's.The patent, which is the corporation's first specifically targeting neurological conditions, is granted for the US market and is valid until 2022. The claims focus on treating Alzheimer's disease by administering an effective amount of a phospholipid composition, wherein the phospholipid composition comprises DHA and EPA. "Today's announcement provides additional strength to our patent estate and highlights our commitment to continue to protect and build this valuable asset for both our nutraceutical and pharmaceutical businesses," highlighted Mr. Henri Harland, President and CEO of Neptune. "Neurological disorders, such as Alzheimer's, are growing and new methods to prevent and treat such conditions using alternative treatments are continuously being sought out. In addition to Neptune, this new patent substantially benefits our subsidiary, NeuroBioPharm, as it continues to develop omega-3 phospholipid products for neurological pharmaceutical applications."
April 21, 2014
14:05 EDTNEPTNeptune says '348 patent still valid, to appeal USPTO decision
Neptune Technologies & Bioressources (NEPT) announced that the United States Patent and Trademark Office, or USPTO, recently issued a Right of Appeal Notice in an inter partes reexamination of Neptune's '348 patent. Despite the USPTO's decision, the '348 patent is still valid as Neptune has the right to appeal, which it intends to do, the company said. "Enzymotec (ENZY), in yet another clear attempt to shift focus from the on-going International Trade Commission investigation of its infringement of other Neptune patents, issued a press release addressing the '348 Patent decision. However, Enzymotec failed to highlight that the decision has no impact on the ITC investigation into infringement of Neptune's other composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. Furthermore, the decision has no impact on Neptune's license agreements with Rimfrost and Aker BioMarine," said Neptune.
08:09 EDTNEPTEnzymotec says USPTO issues final decision, rejects all claims in Neptune patent
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use